Changeflow GovPing Healthcare & Life Sciences TriLink BioTechnologies Modified RNA With 3′-St...
Routine Notice Added Final

TriLink BioTechnologies Modified RNA With 3′-Stabilizing Region

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

TriLink BioTechnologies, LLC has filed US Patent Application US20260109977A1 covering modified RNA molecules where a 3′-stabilizing region is covalently attached to the RNA, and where the 3′-stabilizing region comprises one or more modified nucleosides. The application (No. 19386605) was filed on November 12, 2025, and names eight inventors: Chunping Xu, Chanfeng Zhao, Paul Theodore Ludford III, Dhamodharan Venugopal, Alexandre V. Lebedev, and Hengyuan Lang. This biotechnology patent application relates to methods for increasing protein expression through modified RNA design.

“Described herein are modified RNA molecules where a 3′-stabilizing region is covalently attached to the RNA, and where the 3′-stabilizing region comprises one or more modified nucleosides.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 258 changes logged to date.

What changed

US Patent Application US20260109977A1 describes novel modified RNA molecules featuring a 3′-stabilizing region covalently attached to the RNA, where the 3′-stabilizing region incorporates one or more modified nucleosides. The filing also discloses methods of synthesizing said modified RNA molecules.

For parties involved in RNA therapeutics, vaccine development, or gene expression research, this patent application should be considered during freedom-to-operate analyses. Competitors developing similar 3′-stabilized RNA constructs should review the claims to assess potential overlap with their own product pipelines. The application is currently pending examination by the USPTO.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION

Application US20260109977A1 Kind: A1 Apr 23, 2026

Assignee

TriLink BioTechnologies, LLC

Inventors

Chunping Xu, Chanfeng Zhao, Paul Theodore Ludford, III, Dhamodharan Venugopal, Alexandre V. Lebedev, Hengyuan Lang

Abstract

Described herein are modified RNA molecules where a 3′-stabilizing region is covalently attached to the RNA, and where the 3′-stabilizing region comprises one or more modified nucleosides. Methods of synthesizing said RNAs are also provided herein.

CPC Classifications

C12N 15/11 A61K 31/7115 A61K 31/7125 C12N 15/10 C12N 2310/3515 C12N 2310/531

Filing Date

2025-11-12

Application No.

19386605

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
19386605

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent filing RNA research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!